FDA v. Alliance for Hippocratic Medicine
The Supreme Court unanimously ruled that anti-abortion doctors and medical groups lacked the legal right to bring this case in federal court, because they could not show they were personally harmed by the FDA's rules relaxing access to the abortion drug mifepristone.
The ruling is entirely procedural — it does not say whether the FDA's mifepristone rules are lawful or not — and mifepristone remains available under the FDA's current guidelines.
“An Article III court is not a legislative assembly, a town square, or a faculty lounge.”
The majority explaining why federal courts cannot be used as a general forum to challenge government policies one disagrees with.
How it got here: A federal district court in Texas effectively ordered mifepristone off the market; the Fifth Circuit largely agreed the FDA's 2016 and 2021 rule changes were likely unlawful; the Supreme Court agreed to hear the case and kept mifepristone available while the case proceeded.
The Case in Depth
What happened
Four pro-life medical associations and several individual doctors sued the FDA, arguing that its 2016 and 2021 decisions — which allowed mifepristone to be prescribed through ten weeks of pregnancy, permitted nurse practitioners to prescribe it, and lifted an in-person visit requirement — violated federal law. The plaintiffs wanted the drug restricted or pulled from the market. None of the plaintiffs prescribe or use mifepristone themselves, and the FDA has not required them to do or stop doing anything.
The question before the Court
Could a group of anti-abortion doctors and medical associations sue in federal court to force the FDA to tighten access to the abortion drug mifepristone, even though the doctors themselves don't prescribe or use the drug?
The Court's answer
No — the plaintiff doctors and medical groups did not have the legal right to bring this lawsuit in federal court. To sue under Article III of the Constitution, a plaintiff must show a real, personal injury caused by the defendant's specific conduct. None of the plaintiffs' theories of harm held up: federal conscience laws already fully protect doctors from being forced to perform abortions or provide abortion-related treatment against their beliefs, cutting off that chain of causation; the claim that doctors would face more mifepristone-complication patients and higher costs was too speculative and too many steps removed from the FDA's actions to count; and medical associations cannot manufacture standing simply by spending money to study and lobby against a government policy they oppose.
The Court stressed that sincere moral, ideological, or policy objections to a government action — no matter how deeply felt — are not enough to get into federal court. Those who oppose the FDA's mifepristone rules may press their concerns through Congress, the executive branch, or the political process, but not through federal courts without a more direct personal stake in the outcome.
Curious how the Court got there? See the step-by-step legal reasoning →
Why it matters
Mifepristone stays available under the FDA's current rules, which allow it through ten weeks of pregnancy and via mail-order pharmacies. No court has ruled those rules legal or illegal — the case was thrown out before reaching that question. Anyone wanting to mount a fresh challenge would need to find plaintiffs who can show a direct, concrete, personal harm from the FDA's specific actions.
What changes now
The case returns to the lower federal courts for proceedings consistent with the Supreme Court's ruling. Because the dismissal was on standing grounds, no court has yet decided whether the FDA's 2016 and 2021 mifepristone rule changes were actually lawful. Mifepristone remains available under those rules. A future challenger with a more direct personal stake — such as a state with a concrete interest, or a drug competitor — could potentially bring a new lawsuit, but the Court left that question open.
What this does not decide
The Court did not decide whether the FDA's 2016 or 2021 mifepristone rule changes were legal or illegal under the Administrative Procedure Act. Those merits questions remain entirely unresolved. The ruling also does not address whether a different plaintiff — one with a more direct stake — could successfully challenge the FDA's mifepristone regulations in the future.
Concurrences and dissents
Concurrence — Justice Thomas
Justice Thomas joined the majority in full but wrote separately on two points. First, he reiterated his long-held view that the Court's third-party standing doctrine — which allows plaintiffs to assert someone else's legal rights in certain circumstances — is constitutionally mistaken; the doctors opposing abortion cannot assert their patients' rights any more than abortion providers can assert their clients' rights. Second, and more extensively, he raised serious doubts about associational standing, the doctrine that allows organizations to sue on behalf of their injured members. He argued that doctrine conflicts with Article III's traditional limits, distorts the rules governing class actions and legal preclusion, and was adopted without meaningful constitutional justification — and called for the Court to reexamine it in an appropriate future case.
How the Court got there
The legal reasoning, step by step
- The Court began with Article III's constitutional requirement that only people with a real, personal stake in a dispute can sue in federal court. Standing requires showing three things: a concrete injury in fact affecting the plaintiff personally, a causal link between that injury and the defendant's conduct, and a showing that a court ruling would fix the harm. General moral, ideological, or policy objections to government action, no matter how sincere, do not satisfy these requirements.
- Because the plaintiff doctors and associations don't prescribe or use mifepristone and are not directly regulated by the challenged FDA rules, they are 'unregulated parties' challenging the government's regulation of others — making the causation requirement substantially harder to satisfy. Any injury would have to flow through the independent choices of pregnant women, other physicians, and hospitals, making the causal chain more speculative by nature.
- The Court rejected the conscience-injury theory first. Even assuming FDA's loosened rules led more women to seek emergency treatment from the plaintiff doctors, federal conscience laws — specifically the Church Amendments — clearly and broadly protect any doctor from being required to perform abortions or provide abortion-related treatment that violates their beliefs. Because those protections are comprehensive and have worked without exception since mifepristone's approval in 2000, they break any causal chain between FDA's rules and a forced conscience violation. EMTALA, a federal emergency-care law, does not override those protections.
- The Court next rejected the economic-injury theory. The plaintiffs offered no evidence that FDA's 2016 and 2021 changes actually increased the number of mifepristone complications they treated, making the claimed harms highly speculative. More fundamentally, doctors have never had standing to challenge government safety regulations merely because those rules might send more patients their way — a rule the Court said would otherwise let doctors sue over virtually any public-health policy, from speed limits to emissions standards to gun regulations.
- The Court then rejected the medical associations' claim that they had standing as organizations, based on resources they spent studying mifepristone and petitioning the FDA. An organization cannot 'spend its way into standing' by voluntarily choosing to research or advocate against a policy it dislikes. The 1982 Havens Realty case — where a housing-counseling group had standing because a real estate firm's racial steering directly disrupted the group's core counseling operations — applies only when a defendant's conduct concretely impairs an organization's actual business activities, not merely its advocacy mission.
- Finally, the Court dismissed the argument that the plaintiffs must have standing because otherwise no one could challenge the FDA's mifepristone rules. The Court has long rejected that 'if not us, who?' logic: some issues may simply be left to the political and democratic processes, and the assumption that someone must always be able to sue is not a basis for creating federal jurisdiction where the Constitution does not support it.
Doctrinal impact
Cases affected by this decision
Distinguishes Havens Realty Corp. v. Coleman (455 U. S. 363)
Havens only applies when a defendant's conduct directly disrupts an organization's core business operations, not when an organization voluntarily spends money opposing a policy it dislikes.